Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | AOC2 | O75106 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26138812 | 0.87 | ALDH1A1 (0.40) | ALDH1A1GNAI3GNAO1GNAI1MEN1 | |
| SCHEMBL22585186 | 0.85 | ALDH1A1 (0.39) | ALDH1A1GNAI3GNAO1GNAI1MEN1 | |
| SCHEMBL20381555 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MEN1TSHRKMT2AL3MBTL1 | |
| SCHEMBL20381498 | 0.82 | ALDH1A1 (0.37) | ALDH1A1MEN1TSHRKMT2ANPC1 | |
| SCHEMBL22332225 | 0.81 | ALDH1A1 (0.37) | ALDH1A1MEN1TSHRKMT2AL3MBTL1 | |
| SCHEMBL16591600 | 0.81 | CYP2D6 (0.45) | ALDH1A1MEN1TSHRKMT2AL3MBTL1 | |
| SCHEMBL8430270 | 0.81 | ALDH1A1 (0.46) | ALDH1A1GNAI3GNAO1GNAI1KMT2A | |
| SCHEMBL25039064 | 0.81 | ALDH1A1 (0.57) | ALDH1A1MEN1TSHRKMT2AL3MBTL1 | |
| SCHEMBL22875052 | 0.79 | ALDH1A1 (0.62) | ALDH1A1GNAI3GNAO1GNAI1L3MBTL1 | |
| SCHEMBL26138840 | 0.79 | BDKRB1 (0.38) | ALDH1A1HSD11B1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-20210230183-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-29 | — | — | US | disclosed |
| US-11008334-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885GNAI3 209/4885GNAO1 1080/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | ALDH1A1 2792/4885GNAI3 209/4885GNAO1 1080/4885 |
| US-20210230183-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885GNAI3 209/4885GNAO1 1080/4885 |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885GNAI3 209/4885GNAO1 1080/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885GNAI3 209/4885GNAO1 1080/4885 |
| US-11008334-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | ALDH1A1 2792/4885GNAI3 209/4885GNAO1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.